Expand APM Menu
APM MENU

APM Stock Posts


APM stock increases 41.8% in premarket,

Premarket Gainer

APM Aptorum Group Limited - Class A1.22-0.05-3.9%

Premarket:1.73+0.51 (+41.8%)

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Business WireThu, 20-Jan 8:00 AM
APM stock increases 57.2% in premarket,

Premarket Gainer

APM Aptorum Group Limited - Class A3.18-0.13-3.9%

Premarket:5.00+1.82 (+57.2%)

Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Business WireWed, 20-Jan 6:00 AM
APM stock declines -30.9% in premarket,

Premarket Decliner

APM Aptorum Group Limited - Class A4.76+3.54+290.2%

Premarket:3.29-1.47 (-30.9%)

Aptorum Group Announces Pricing of $9.0 Million Public Offering

Business WireTue, 29-Sep 9:00 PM
Load Earlier Posts